Suven Life Sciences gets product patents from Canada, Sri Lanka for a new chemical entity
Suven Life Sciences Tuesday said it has been granted a product patent by Canada and Sri Lanka each for a new chemical entity (NCE) used in the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2034 and 2026, respectively, the company said in a BSE filing.
"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena, which is being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.
The granted claims of patents are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), Huntington's disease, Parkinson's and schizophrenia, it added.